A Phase II/III Study of Sargramostim

  • days left to enroll
  • participants needed
  • sponsor
Updated on 16 May 2021
Masaki Taniguchi
Primary Contact
Japanese Red Cross Society Saitama Red Cross Hospital (9.6 mi away) Contact
+6 other location


This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment in COVID-19 patients.

Condition *COVID-19, Covid-19
Treatment Placebo, sargramostim
Clinical Study IdentifierNCT04642950
Last Modified on16 May 2021


Yes No Not Sure

Inclusion Criteria

Japanese male or female subjects who have been confirmed to meet all the
following criteria
Hospitalized patients under treatment who were severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] positive by polymerase chain reaction (PCR) test
Patients with clinically diagnosed pneumonia and a percutaneous oxygen saturation [SpO2] of 93% or less on breathing of room air at bed rest
Patients for whom written informed consent has been obtained from those themselves or the legally acceptable representatives
Patients aged 20 years or older and younger than 85 years at the time of obtaining informed consent

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded. Unless
otherwise stated, the following criteria refer to those at the time of
Patients who have been participating in other intervention studies, such as studies on unapproved pharmacotherapy, within 90 days prior to screening
Patients who have experienced off-label use of approved drugs (including those for COVID-19 treatment other than steroids as standard treatment) within 7 days prior to screening
Patients who are not expected to survive longer than 24 hours after commencement of study drug administration
Patients who are using invasive ventilator or extracorporeal membrane oxygenation (ECMO)
Patients who have a chronic respiratory disease requiring continuous home oxygen therapy or ventilator use
Patients with an underlying condition that is considered very unlikely to withdraw ventilator (e.g., motor neuron disease, Duchenne muscular dystrophy, rapidly progressive interstitial pulmonary fibrosis)
Patients who have a disease including bronchial asthma, lower respiratory tract infections, and interstitial lung diseases that may affect the assessment of the clinical study, since before the symptom onset of COVID-19
Patients who have a disease including leukemia and leukocytosis that causes leukocytosis
Patients who have a chronic kidney disease requiring dialysis
Patients who have severe liver failure (Child Pugh grade C)
Patients aged 80 years or older with any of heart failure, cerebrovascular disease, obesity (BMI 30 or higher), dyslipidemia, hypertension or diabetes
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note